<DOC>
	<DOCNO>NCT00432575</DOCNO>
	<brief_summary>Surinabant new , potent selective antagonist cannabinoid CB1 receptor , might clinically useful treatment dependence nicotine . The primary study objective assessment efficacy 3 dos surinabant abstinence smoking cigarette smoker . The main secondary objective effect surinabant body weight clinical biological safety .</brief_summary>
	<brief_title>Efficacy Safety Surinabant Treatment Aid Smoking Cessation ( SURSMOKE )</brief_title>
	<detailed_description />
	<mesh_term>Surinabant</mesh_term>
	<criteria>Patients legal age smoking least 10 cigarettes/day mean within 6 month precede screen visit . Patients limited level motivation . Other participant household enrol study . Patients smoke consumed nontobacco cigarette form tobacco product 3 day within 3 month precede screen visit . Patients dependent alcohol illicit drug . Patients diagnosis Psychotic Disorder currently present Depressive Episode . Patients suffer myocardial infarction , unstable angina major cardiovascular event within past 6 month prior screen . Pregnant breastfeed woman woman protect effective contraceptive method birth control . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>tobacco use cessation</keyword>
	<keyword>cigarette smoker</keyword>
</DOC>